242 related articles for article (PubMed ID: 28348063)
1. Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.
Kasztan M; Fox BM; Speed JS; De Miguel C; Gohar EY; Townes TM; Kutlar A; Pollock JS; Pollock DM
J Am Soc Nephrol; 2017 Aug; 28(8):2443-2458. PubMed ID: 28348063
[TBL] [Abstract][Full Text] [Related]
2. Combined hydroxyurea and ET
Taylor C; Kasztan M; Tao B; Pollock JS; Pollock DM
Acta Physiol (Oxf); 2019 Feb; 225(2):e13178. PubMed ID: 30144292
[TBL] [Abstract][Full Text] [Related]
3. Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice.
Saurage E; Davis PR; Meek R; Pollock DM; Kasztan M
Can J Physiol Pharmacol; 2022 Jul; 100(7):637-650. PubMed ID: 35413222
[TBL] [Abstract][Full Text] [Related]
4. Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice.
Kasztan M; Pollock DM
Clin Sci (Lond); 2019 Jul; 133(13):1475-1486. PubMed ID: 31273050
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species.
Heimlich JB; Speed JS; O'Connor PM; Pollock JS; Townes TM; Meiler SE; Kutlar A; Pollock DM
Br J Pharmacol; 2016 Jan; 173(2):386-95. PubMed ID: 26561980
[TBL] [Abstract][Full Text] [Related]
6. Endothelin ET
Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
8. Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.
Kasztan M; Fox BM; Lebensburger JD; Hyndman KA; Speed JS; Pollock JS; Pollock DM
Blood Adv; 2019 May; 3(9):1460-1475. PubMed ID: 31064747
[TBL] [Abstract][Full Text] [Related]
9. Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis.
Sumida H; Asano Y; Hatano M; Aozasa N; Toyama T; Akamata K; Miyazaki M; Taniguchi T; Takahashi T; Ichimura Y; Noda S; Kuwano Y; Yanaba K; Sato S
Mod Rheumatol; 2016; 26(3):454-7. PubMed ID: 24593173
[TBL] [Abstract][Full Text] [Related]
10. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.
Muthuraman A; Nafisa K; Sowmya MS; Arpitha BM; Choedon N; Sandy CD; Rishitha N; Johurul I
Life Sci; 2019 Apr; 222():133-139. PubMed ID: 30844374
[TBL] [Abstract][Full Text] [Related]
11. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G; Behr J; Brown KK; Egan JJ; Kawut SM; Flaherty KR; Martinez FJ; Nathan SD; Wells AU; Collard HR; Costabel U; Richeldi L; de Andrade J; Khalil N; Morrison LD; Lederer DJ; Shao L; Li X; Pedersen PS; Montgomery AB; Chien JW; O'Riordan TG;
Ann Intern Med; 2013 May; 158(9):641-9. PubMed ID: 23648946
[TBL] [Abstract][Full Text] [Related]
12. Renal protection by atorvastatin in a murine model of sickle cell nephropathy.
Zahr RS; Chappa P; Yin H; Brown LA; Ataga KI; Archer DR
Br J Haematol; 2018 Apr; 181(1):111-121. PubMed ID: 29527679
[TBL] [Abstract][Full Text] [Related]
13. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure-independent manner.
Trenkner J; Priem F; Bauer C; Neumayer HH; Raschak M; Hocher B
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():385S-388S. PubMed ID: 12193128
[TBL] [Abstract][Full Text] [Related]
15. Urinary Transforming Growth Factor β-1 as a Marker of Renal Dysfunction in Sickle Cell Disease.
Ghobrial EE; Abdel-Aziz HA; Kaddah AM; Mubarak NA
Pediatr Neonatol; 2016 Jun; 57(3):174-80. PubMed ID: 26508723
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the protective effects of selective endothelin-a receptor antagonist, ambrisentan, and dual endothelin-A/B receptor antagonist, bosentan, in experimental renal ischemia reperfusion injury.
Kazimoglu H; Uysal E; Dokur M; Gurer AO; Batcioglu K; Uyumlu BA; Petekkaya E; Karadag M
Bratisl Lek Listy; 2020; 121(8):547-553. PubMed ID: 32726116
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.
Fox BM; Kasztan M
Life Sci; 2016 Aug; 159():15-19. PubMed ID: 27049871
[TBL] [Abstract][Full Text] [Related]
19. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition.
Ortmann J; Amann K; Brandes RP; Kretzler M; Münter K; Parekh N; Traupe T; Lange M; Lattmann T; Barton M
Hypertension; 2004 Dec; 44(6):974-81. PubMed ID: 15545511
[TBL] [Abstract][Full Text] [Related]
20. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.
Stuart D; Chapman M; Rees S; Woodward S; Kohan DE
J Pharmacol Exp Ther; 2013 Aug; 346(2):182-9. PubMed ID: 23709116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
